TMCI - Treace Medical Concepts, Inc.

Treace to Report Third Quarter 2026 Financial Results on November 6, 2026

PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2026 before the start of trading on Friday, November 6, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

Oct 23, 2026 03:05 AM • globenewswire.com

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 26, 2026Shareholders are encouraged to conta

Sep 25, 2026 09:00 PM • gurufocus.com

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Sep 25, 2026 08:43 PM • prnewswire.com

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society (“AOFAS”) Annual Meeting in Seattle, Washington. The presentations include data on the milestone 5-year ALIGN3D® Lapiplasty®, the MTA3D® Adductoplasty® and the SPRINT™ SpeedPlate® clinical studies.

Sep 17, 2026 01:16 PM • globenewswire.com

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies

Sep 15, 2026 01:06 PM • globenewswire.com

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Aug 07, 2026 12:24 PM • seekingalpha.com

Treace Medical Concepts Q2 Earnings Call Highlights

Treace Medical Concepts NASDAQ: TMCI reported second-quarter 2026 revenue of $45.4 million, down 4% from the prior-year period, as lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products weighed on reported sales.

Aug 07, 2026 10:04 AM • marketbeat.com

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.28 per share a year ago.

Aug 07, 2026 05:20 AM • zacks.com

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026.

Aug 07, 2026 03:05 AM • globenewswire.com

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Jul 24, 2026 10:24 AM • prnewswire.com

Treace to Report Second Quarter 2026 Financial Results on August 7, 2026

PONTE VEDRA, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the second quarter 2026 before the start of trading on Friday, August 7, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

Jul 24, 2026 03:05 AM • globenewswire.com

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI) against certain of its officers and directors for alleged breaches of fiduciary duty.

Jul 13, 2026 05:49 AM • globenewswire.com (Hide legal announcements)

Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System

New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base

Jun 18, 2026 03:05 AM • globenewswire.com

Treace to Present at the Sidoti Small Cap Conference

PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will present at the Sidoti Small Cap Conference, Thursday, June 18, 2026, beginning at approximately 1:45 pm ET.

Jun 11, 2026 12:05 PM • globenewswire.com

Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ: TMCI). The investigation focuses on Treace's executive officers and whether investor losses may be recovered under federal securities laws.

May 12, 2026 04:05 AM • globenewswire.com (Hide legal announcements)

Treace Medical Concepts Q1 Earnings Call Highlights

Treace Medical Concepts NASDAQ: TMCI reaffirmed its full-year 2026 revenue outlook after reporting a first-quarter revenue decline, as management said new product adoption is helping drive procedure volume momentum despite pricing and mix headwinds.

May 08, 2026 08:08 PM • marketbeat.com

Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript

Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript

May 08, 2026 07:01 AM • seekingalpha.com

Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.25 per share a year ago.

May 08, 2026 05:26 AM • zacks.com

Treace Medical Concepts Reports First Quarter 2026 Financial Results

PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026.

May 08, 2026 03:05 AM • globenewswire.com

Treace to Report First Quarter 2026 Financial Results on May 8, 2026

PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

Apr 24, 2026 03:05 AM • globenewswire.com

Treace Medical price target lowered to $3 from $5 at Stifel

$3.00 (was $2.92)

Stifel Nicolaus

Jan 07, 2026 07:35 AM • TheFly

Treace Medical price target lowered to $3 from $4 at Truist

$3.00 (was $2.54)

Richard Newitter · Truist Financial

Dec 18, 2025 09:15 AM • TheFly

Treace Medical price target lowered to $4 from $7 at Truist

$4.00 (was $3.86)

Richard Newitter · Truist Financial

Nov 10, 2025 10:07 AM • TheFly

Treace Medical price target lowered to $7 from $8 at Truist

$7.00 (was $6.20)

Truist Financial

Oct 15, 2025 08:47 AM • TheFly

Treace Medical price target raised to $8 from $6.60 at Truist

$8.00 (was $7.25)

Truist Financial

Sep 03, 2025 03:58 PM • TheFly

Treace Medical price target lowered to $9.50 from $10 at Truist

$9.50 (was $7.94)

Truist Financial

Mar 13, 2025 08:19 AM • TheFly

Treace Medical upgraded to Buy from Neutral at BTIG

$16.00 (was $10.51)

Ryan Zimmerman · BTIG

Feb 04, 2025 06:06 AM • TheFly

Treace Medical initiated with a Buy at Lake Street

$14.50 (was $7.44)

Ben Haynor · Lake Street

Dec 31, 2024 07:45 AM • TheFly

Treace Medical downgraded to Neutral from Buy at UBS

$6.50 (was $5.95)

Danielle Antalffy · UBS

May 16, 2024 12:36 AM • TheFly

BTIG Maintains Buy on Treace Medical Concepts, Raises Price Target to $28

$28.00 (was $23.95)

BTIG

Sep 21, 2022 05:19 AM • Benzinga

Stifel Maintains Buy on Treace Medical Concepts, Raises Price Target to $27

$27.00 (was $23.87)

Stifel Nicolaus

Sep 21, 2022 04:35 AM • Benzinga

Stifel Maintains Buy on Treace Medical Concepts, Lowers Price Target to $21

$21.00 (was $16.29)

Stifel Nicolaus

Jul 18, 2022 05:51 AM • Benzinga